The EIIIA Domain from Astrocyte-Derived Fibronectin Mediates Proliferation of Oligodendrocyte Progenitor Cells Following CNS Demyelination

Josephine M. J. Stoffels,1 Dick Hoekstra,1 Robin J. M. Franklin,2 Wia Baron,1 and Chao Zhao2

Central nervous system remyelination by oligodendrocyte progenitor cells (OPCs) ultimately fails in the majority of multiple sclerosis (MS) lesions. Remyelination benefits from transient expression of factors that promote migration and proliferation of OPCs, which may include fibronectin (Fn). Fn is present in demyelinated lesions in two major forms; plasma Fn (pFn), deposited following blood-brain barrier disruption, and cellular Fn, synthesized by resident glial cells and containing alternatively spliced domains EIIIA and EIIIB. Here, we investigated the distinctive roles that astrocyte-derived Fn (aFn) and pFn play in remyelination. We used an inducible Cre-lox recombination strategy to selectively remove pFn, aFn or both from mice, and examined the impact on remyelination of toxin-induced demyelinated lesions of spinal cord white matter. This approach revealed that astrocytes are a major source of Fn in demyelinated lesions. Furthermore, following aFn conditional knockout, the number of OPCs recruited to the demyelinated lesion decreased significantly, whereas OPC numbers were unaltered following pFn conditional knockout. However, remyelination completed normally following conditional knockout of aFn and pFn. Both the EIIIA and EIIIB domains of aFn were expressed following demyelination, and in vitro assays demonstrated that the EIIIA domain of aFn mediates proliferation of OPCs, but not migration. Therefore, although the EIIIA domain from aFn mediates OPC proliferation, aFn is not essential for successful remyelination. Since previous findings indicated that astrocyte-derived Fn aggregates in chronic MS lesions inhibit remyelination, aFn removal may benefit therapeutic strategies to promote remyelination in MS.

Key words: fibronectin, astrocyte, oligodendrocyte, remyelination, multiple sclerosis

Introduction

Multiple sclerosis (MS) is a central nervous system (CNS) disease, of which inflammation, demyelination, and axonal loss are the main pathological features. Regeneration of myelin (remyelination) involves proliferation and migration of activated oligodendrocyte progenitor cells (OPCs) to demyelinated lesions, and their subsequent differentiation into myelinating oligodendrocytes (Franklin and ffrench-Constant, 2008; Zawadzka et al., 2010). The extent of remyelination in MS is variable, but often is insufficient to prevent chronic axonal loss (Franklin et al., 2012; Patrikios et al., 2006). Promoting endogenous remyelination provides a means to reduce axonal degeneration and thereby slow progression of clinical disability (Duncan et al., 2009; Franklin et al., 2012).

Fibronectin (Fn) is an extracellular matrix (ECM) protein, that is essential for embryonic development (George et al., 1993). In healthy adults, Fn is continuously produced by hepatocytes and circulates in the plasma. Fn is absent from the healthy CNS, but expressed following injury, which...

The copyright line for this article was changed on 9 July 2015 after original online publication.

View this article online at wileyonlinelibrary.com. DOI: 10.1002/glia.22748

Published online August 25, 2014 in Wiley Online Library (wileyonlinelibrary.com). Received June 12, 2014, Accepted for publication Aug 11, 2014.

Address correspondence to Chao Zhao, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute and Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0AH, United Kingdom. E-mail: cz213@cam.ac.uk

From the 1Department of Cell Biology, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. E-mail: w.baron@umcg.nl

From the 1Department of Cell Biology, University of Groningen, University Medical Center Groningen, The Netherlands; 2Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute and Department of Clinical Neurosciences, University of Cambridge, United Kingdom.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
includes demyelination. Plasma Fn (pFn) leaks across a disrupted blood-brain barrier (Satoh et al., 2009; Sobel and Mitchell, 1989; van Horssen et al., 2005), and cellular Fn (aFn) is primarily synthesized by astrocytes (Hibbits et al., 2012; Stoffels et al., 2013a), but also by microglia/macrophages and endothelial cells (Stoffels et al., 2013a). In contrast to pFn, cellular Fn may contain alternatively spliced domains, named EIIIA, EIIIB, and the V-region in rodents (EDA, EDB, and IIICS, respectively, in humans; Paul et al., 1986; Schwarzbauer et al., 1987). In vitro, pFn stimulates migration and proliferation of OPCs at low growth factor levels via αv integrin receptors, the only integrin receptors for Fn present on OPCs (Baron et al., 2002; Blaschuk et al., 2000; Milner and ffrench-Constant, 1994; Milner et al., 1996). The expression of both Fn and αv integrins is transiently increased in demyelinated lesions (Stoffels et al., 2013a; Zhao et al., 2009). Therefore, Fn may contribute to remyelination by promoting OPC recruitment. However, at later stages of oligodendrocyte maturation, removal of Fn is required for remyelination to proceed to completion, since Fn inhibits myelin sheet formation (Buttery and ffrench-Constant, 1999; Maier et al., 2005; Siskova et al., 2006, 2009). In addition, Fn aggregates impair OPC differentiation in vivo, and likely contribute to remyelination failure in MS (Stoffels et al., 2013a).

Here, we explored the role of Fn in more depth by asking what distinctive roles the two Fn variants, pFn and astrocyte-derived Fn (aFn), play in remyelination. Using an inducible Cre-lox recombination strategy to selectively remove pFn, aFn or both (Hirrlinger et al., 2006; Sakai et al., 2001) in combination with a well-established model of CNS demyelination (Blakemore and Franklin, 2008), we found that conditional knockout of aFn, but not pFn, reduced the density of OPCs. In vitro analysis revealed that this was likely mediated by the EIIIA domain, which mediates OPC proliferation on aFn at sufficient growth factor levels. However, although conditional knockout of aFn was associated with reduced OPC numbers following demyelination, it was not sufficient to affect the remyelination outcome. The translational implication of our data therefore is that elimination of aFn may be amenable in MS to prevent the formation of remyelination-inhibiting Fn aggregates. This will likely be beneficial in promoting endogenous remyelination (Stoffels et al., 2013a).

Materials and Methods

Mice

Mice were housed under standard conditions. All experiments were performed in compliance with United Kingdom Home Office regulations. Plasma Fn (pFn) inducible, conditional knockout mice (hereafter referred to as pFn
t isogenic mice were a kind gift from Dr. R. Fassler, Max Planck Institute for Biochemistry, Martinsried, Germany. Inducible, conditional knockout (hereafter referred to as “conditional knockout”) of pFn was created as described (Sakai et al., 2001). Briefly, floxed Fn mice were crossed with mice expressing Cre recombinase under the control of the polyinosinic-polycytidic acid (poly I:C) responsive Ms promoter (Mx-Cre). On Cre-mediated recombination at the loxp sites, the start codon, signal sequence and the exon/intron border of exon 1 are removed from the Fn gene to generate the null allele (Sakai et al., 2001). Cre-mediated recombination was induced in hepatocytes from the 6-week old mice carrying Mx-Cre by two intraperitoneal injections of poly I:C (GE Healthcare, Amersham, UK) with a 48 h interval as previously described (Sakai et al., 2001). Wild type (WT) control mice received vehicle only (phosphate-buffered saline; PBS). Mice were subjected to lysolecithin-induced demyelination at 2–3 weeks following induction of the knockout.

Conditional knockout mice devoid of aFn (astrocyte Fn; aFn
t was achieved by breeding mice heterozygous for the EIIIA domain, which mediates OPC proliferation on aFn at sufficient growth factor levels. However, although conditional knockout of aFn was associated with reduced OPC numbers following demyelination, it was not sufficient to affect the remyelination outcome. The translational implication of our data therefore is that elimination of aFn may be amenable in MS to prevent the formation of remyelination-inhibiting Fn aggregates. This will likely be beneficial in promoting endogenous remyelination (Stoffels et al., 2013a).

Here, we explored the role of Fn in more depth by asking what distinctive roles the two Fn variants, pFn and astrocyte-derived Fn (aFn), play in remyelination. Using an inducible Cre-lox recombination strategy to selectively remove pFn, aFn or both (Hirrlinger et al., 2006; Sakai et al., 2001) in combination with a well-established model of CNS demyelination (Blakemore and Franklin, 2008), we found that conditional knockout of aFn, but not pFn, reduced the density of OPCs. In vitro analysis revealed that this was likely mediated by the EIIIA domain, which mediates OPC proliferation on aFn at sufficient growth factor levels. However, although conditional knockout of aFn was associated with reduced OPC numbers following demyelination, it was not sufficient to affect the remyelination outcome. The translational implication of our data therefore is that elimination of aFn may be amenable in MS to prevent the formation of remyelination-inhibiting Fn aggregates. This will likely be beneficial in promoting endogenous remyelination (Stoffels et al., 2013a).

Lysolceithin-Induced Demyelination of the Spinal Cord and Tissue Processing

Surgery and tissue processing were performed as described (Zhao et al., 2006). Briefly, mice at about 9–10 weeks old were anaesthetized with isoflurane, and spinal cord lesions were created by direct injection of 1 μL 1% lysolceithin into the ventral funiculus through a gap between two thoraco-lumbar vertebrae. In the conditional knockout mice, lesions were induced 1–2 weeks after completing the induction protocol. Blood samples were obtained for isolating plasma from the tail at the time of lesion, and collected in citrate-dextrose solution (Sigma-Aldrich, Dorset, UK), then stored at −80°C until use.

At the designated time post lesion, mice were euthanized by intraperitoneal injection of pentobarbital following by appropriate protocols of tissue processing. For immunohistochemistry and in situ hybridization, mice were perfusion fixed with 4% phosphate-buffered paraformaldehyde (PFA) solution via the left ventricle, after which the dissected spinal cord containing the lesions was either directly frozen at −80°C for later RNA extractions, or treated with 20% sucrose in PBS overnight. Cords were embedded in OCT (Thermo Fisher Raymond Lamb, Loughborough, UK), and cut in
coronal sections at 12 μm thickness. These sections were mounted on poly-l-lysine (PLL)-coated slides (Poly sciences Europe GmbH Eppelheim, Germany) and stored at −80°C until further use. For resin embedding and semi-thin sectioning, mice were perfused with 4% phosphate-buffered gluteraldehyde and subjected to a standard resin embedding process (Zhao et al., 2006). Semi-thin sections of 1 μm were cut and stained with alkaline toluidine blue. Ranking analysis on semi-thin sections of remyelinated lesions was performed by two independent, blinded researchers as described (Ibanez et al., 2004).

**Glial Cell Cultures**

Primary glial cell cultures were generated from 1 to 2 day old Wistar rats (Harlan, the Netherlands) as previously described (Baron et al., 2002; Bisbsi et al., 2012). Briefly, after 10–12 days in culture on PLL (5 μg/mL, Sigma-Aldrich, St. Louis, MO) coated flasks, OPCs and astrocytes were isolated via a shake-off procedure (McCarthy and de Vellis, 1980). Contaminating microglia were removed by shaking the flasks at 150 rpm for 1 h at 37°C on an orbital shaker. Subsequently, flasks were shaken at 240 rpm overnight at 37°C. Floating OPCs were further purified by differential adhesion. Then, OPCs were cultured in defined Sato medium (Maier et al., 2005) on appropriate cell culture plastics for the different assays (see below). Purity of the OPC cultures was routinely assessed by immunochemistry for Olig2 (1:1000; Millipore, Billerica, MA) and cultures used were >97% pure.

To obtain astrocytes, a subsequent overnight shake off was performed at 240 rpm and the remaining astrocyte monolayer was removed by trypsin. Astrocytes were cultured in T162 flasks (Corning Costar, Lowell, MA) in DMEM (Life Technologies, Paisley, UK) containing 10% fetal calf serum (FCS; Bodinco, Alkmaar, The Netherlands) and antibiotic supplements (Life Technologies), and passaged once before experimental use. Regular immunocytochemistry for Olig2 (1:1000; Millipore, Billerica, MA) and cultures used were >97% pure.

**Plasma and Astrocyte-Derived Fibronectin Coatings**

To obtain aFn, astrocytes were cultured on 10 cm dishes (Corning) for 48 h, followed by water-lysis at 37°C. The remaining astroglial matrix was scraped in sterile PBS containing Complete Mini protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), followed by protein concentration determination with Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin (BSA) as standard. Then, 8-well chamber-slides were incubated with 8 μg pFn from serum (Sigma-Aldrich) or 8 μg of pFn or aFn per well. Then, membrane proteins were allowed to adhere for 1 h at 37°C, followed by a gentle wash with PBS and seeding of OPCs. Blocking antibodies used were: mouse anti-Fn IST9 (directed against the EIIE domain, Abcam, Cambridge, UK) and mouse anti-Fn C6 (directed against the EIIB domain, Abcam). Notably, the aFn preparation also contains other astroglial matrix proteins, such as laminin (Liesi et al., 1983, 1984) and chondroitin sulphate proteoglycans (Lau et al., 2012), but although these proteins may affect OPC adhesion, proliferation and migration also (Hu et al., 2009; Lau et al., 2012; Milner et al., 1996), EIIEA and EIIEB are exclusively present in aFn.

**SDS-PAGE and Western Blotting**

Equal amounts of plasma from pFnKO and a + pFnKO mice and their controls were mixed with standard SDS sample buffer, heated for 10 min at 95°C, and separated by electrophoresis on SDS-PAGE gels (8%, Expe dawn, Cambridge, UK) for 1 h at 150 V. Protein was transferred to a PVDF membrane (Invitrogen, Paisley, UK) using a wet blotting system (Expedeawn, Cambridge, UK) and according glycine-Tris-methanol buffer. After three washes with 0.1% Tween-20 in PBS, membranes were blocked with 5% non-fat milk solution and incubated with a rabbit anti-Fn antibody (Millipore, Watford, UK; 1:10,000) in blocking buffer, overnight at 4°C. Membranes were washed, and incubated with HRP-conjugated anti-rabbit antibody (Roche, Lewes, UK; 1:1000) in washing buffer. Signals were detected using enhanced chemiluminescence plus (ECL plus; GE Healthcare, Amersham, UK) followed by exposure on suitable X-ray film (Thermo Scientific, Rockford, IL). For detection of mouse IgG as a control, membranes were washed and incubated with biotinylated donkey antimouse IgG antibody (Jackson ImmunoResearch Laboratories, Newmarket, UK; 1:1000) for 1 h, after which the Vectastain ABC Elite kit (Vector Laboratories, Peterborough, UK) was used according to the manufacturer’s instructions, and signals were developed as described above.

**Immunohistochemistry**

Frozen spinal cord sections were air dried for ~1 h and immunohistochemistry was performed as described (Stoffels et al., 2013a) using antibodies against Fn (Millipore; 1:1000), Olig2 (Millipore; 1:1000; R&D Systems, Abingdon, UK; 1:200), Sox2 (Santa Cruz Biotechnology Inc, Dallas, TX; 1:500), Ki67 (Abcam; 1:1000), and Iba1 (Abcam; 1:500). Antigen retrieval was performed before immunostaining with Olig2, using target retrieval solution (DAKO, Ely, UK) at 95°C for 20 min. Immunohistochemistry on coated aFn was performed as described (Stoffels et al., 2013a), using antibodies against Fn (1:50), IST9 (1:50), and C6 (1:50). Secondary antibodies used were appropriate Alexa Fluor® (488 or 594)-conjugated secondary antibodies (Invitrogen; 1:500).

For immunohistochemistry using primary antibodies generated in mice on mouse tissue, a modified protocol was used. This protocol was applied for primary antibodies against Nkx2.2 (Developmental Studies Hybridoma Bank, Iowa, IA; 1:100), CC1 (Millipore; 1:100) and Aldh1L1 (NeuroMab, Davis, CA; 1:100) and secondary antibodies used were Alexa Fluor® 488-conjugated-anti IgG2b (for Nkx2.2 and CC1) or -anti IgG1 (for Aldh1L1; Invitrogen; 1:400). Sections were first permeabilized with 1% Triton-X-100 in 0.05 M Tris-buffered saline (TBS) for 30 min. Then, sections were blocked for 30 min in TBS with 10% normal goat serum (NGS) and 0.25% Triton-X-100, followed by another blocking step for 1 h using mouse-on-mouse Ig solution (Vector Laboratories) according to the manufacturer’s instructions. Primary antibodies were appropriately
diluted in TBS containing 2% NGS and 0.3% Triton-X-100, and applied for 1 h. Secondary antibodies were appropriately diluted in TBS with 1% NGS, 0.1% Triton-X-100 and DAPI (1 μg/mL), and applied for 15 min, followed by a 10 min incubation in 0.1% Sudan Black in 70% ethanol. All incubations were at room temperature. After each step, sections were washed in 0.05 M TBS with 0.1% Tween-20 (VWR, Lutterworth, UK) 3 times 2 min.

Images from immunohistochemistry with either protocol were acquired using a Zeiss Observer A1 fluorescent microscope, and images from immunocytochemistry on coatings were acquired using a Zeiss Axioskop 2 microscope with Leica Application Suite V3 software. For counting cell numbers, in each animal 3 demyelinated lesion levels were selected, spanning the centre of lesions, at ~120 μm distance from each other. The outline of each lesion was defined based on the increase in DAPI cellularity inside the lesion using Zeiss Axiovision 4.8 software, which corresponds to the demyelinated area as stained for Sudan Black (Stoffels et al., 2013a). The numbers of marker-positive cells inside the lesions were manually counted three times and averaged for each lesion. There were 4–5 mice per group. To allow for quantitative comparison, sections were counted in parallel and image acquisitions were performed on the same day using identical camera settings. Individual Fn- and Iba1-immunoreactive cells could not be discerned reliably, hence these were quantified by measuring the optical densities from immunofluorescence using FIJI software.

**In Situ Hybridization**

The DIG-labeled PLP probe was obtained as described (Chari et al., 2006), using mouse PLP cDNA (a kind gift from I.R. Griffiths, Glasgow, UK) that was cloned into the pGEM4 plasmid (Promega, Southampton, UK). To obtain the Fn probe, a cDNA fragment was generated by reverse transcription PCR, using total RNA isolated from WT mouse liver and the following Fn primers: forward: 5'-GTAGTGCTCATATCAGAACC-3' and reverse: 5'-GGACACCATGCA-3'. The cDNA was inserted into the pGEM4 plasmid (Promega, Southampton, UK). For both the PLP and Fn probes, antisense digoxigenin labeled cRNA probes (riboprobes) were then synthesized with appropriate RNA polymerase using a digoxigenin (DIG) RNA labeling kit (Roche, Lewes, UK). The size of the riboprobes was checked by agarose gel electrophoresis. *In situ* hybridization was then performed on air dried spinal cord sections as described previously (Chari et al., 2006).

**Real-Time PCR**

Total RNA was isolated from tissue homogenates using the RNeasy Mini kit (Qiagen). Reverse transcription of 0.5 μg total RNA was performed in the presence of oligo(dT)12–18 and dNTPs (Invitrogen) with SuperScript_II reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. Real-time qPCR was performed using the Applied Biosystems 7900HT Real-Time PCR System. Each reaction contained 5 ng cDNA, 10 pM primers (listed in Table 1) and Absolute SYBR Green Rox mix (Thermo Scientific, Landsmeer, NL). No-template controls were performed to ensure that amplification was not a result of contamination with genomic DNA. Gene expression levels were analyzed using the 2^(-ΔΔct) method (Livak, 2001), and relative expression to HPRT1 or GAPDH. Similar results were observed for both housekeeping genes.

**BrdU Incorporation Assay**

OPCs were plated on 8-well Permanax chamber-slides (Nunc, Naperville, IL), precoated with 5 μg/mL PLL followed by appropriate aFn or pFn coatings (described above), at a density of 30,000 cells per well. OPCs were allowed to incorporate 5-bromo-2-deoxyuridine (BrdU; 10 μM; Roche) for 24 h in the presence of 10 ng/mL PDGF-AA and 10 ng/mL FGF-2. Then, cells were fixed in 4% PFA for 20 min, and additionally fixed in 5% acetic acid in ethanol for 20 min. BrdU was detected using reagents from the BrdU labeling and Detection Kit I (Roche) according to the manufacturer’s instructions with the addition of the oligodendrocyte lineage marker Olig2 (Abcam) and Alexa Fluor® 546-conjugated anti-rabbit antibody, and visualization of nuclei with DAPI (1 μg/mL). To compare the percentages of BrdU-incorporating cells between the conditions, the numbers of double BrdU- and Olig2-positive cells were counted relative to the Olig2-positive cells (at least 150 cells per condition) from images captured with a Leica TCS SP8 Confocal Laser Scanning microscope.

**Transwell Migration Assay**

OPCs were seeded on pFn or aFn coated-polyethylene terephthalate membranes of 8 μm pore size (Becton-Dickinson Labware) in 12-well modified Boyden transwell microchambers at a density of 80,000 cells per insert. OPCs were allowed to migrate through the membranes for 4 h using 10 ng/mL PDGF-AA as a chemoattractant in the bottom of the well. Nonmigrating cells were removed from the top compartment with a cotton swab. Remaining cells in the

| Primer Sequences for Real-Time qPCR | Sense | Anti-sense |
|------------------------------------|-------|------------|
| EIIIA-fibronectin                   | GTTAGTGTCTATGCTCAGAACC | TCCACATCAGTGAATGCCAG |
| EIIIB-fibronectin                   | AAAAGATGACAGAAAGTGCCC  | ATGGTGGAAAGATTAGCGG  |
| Fibronectin                         | GTGAAAGGGAACCAGCAGAG  | CTTGAAGCCAAATCCTTGAG |
| HPRT1                              | GACTTGCTCGAGATGTCA     | TGTAAACCAGCAGTCA     |
| GAPDH                              | CATCAAGAGGTTGGTGAAGC   | ACCACCCGTGTTGCTTAG   |
membranes were fixed for 20 min in 5% acetic acid in ethanol and nuclei were visualized using DAPI (1 μg/mL) in PBS for 30 min. After washing in PBS, membranes were mounted on glass slides and images of DAPI-positive, migrated cells were captured using a Zeiss Axioskop 2 plus microscope with Leica Application Suite v3 software (15 × 20 fields per membrane). The numbers of cells were assessed using FIJI software.

**Adhesion Assay**
pFn or aFn coated 96-wells plates (Nunc) were blocked for 30 min with 1% heat-inactivated BSA at 37°C. Then, wells were left untreated or treated with the Fn blocking antibodies against EIIIA or EIIIB (mouse anti-Fn IST9; Abcam and anti-Fn C6; Abcam). After washing, 10,000 OPCs in 50 μL Sato medium per well were allowed to adhere for 1 h at 37°C. For integrin blocking experiments, OPCs were preincubated with anti-integrin β1 (Rector Dickinson Pharmingen, Breda, NL; 1:200), anti-integrin β3 (Rector Dickinson Pharmingen; 1:200) or anti-integrin β5 (Millipore, Chemicon, Temecula, CA; 1:200) antibodies for 30 min at 37°C. The cells were washed two times with PBS, and adhered cells were fixed for 15 min with ice-cold methanol. Cells were stained with 0.2% crystal violet (in 2% ethanol; Sigma), then washed several times with water, after which the stain was solubilized in 1% SDS. Adhesion was quantified by measuring the absorbance at 570 nm after 30 min. In each independent experiment, adhesion is expressed as percentage of the corresponding untreated substrate control resulting from triplicate determinations.

**Statistical Analyses**
Statistical analyses were performed in GraphPad Prism (GraphPad, La Jolle, CA). First, the Kolmogorov-Smirnov test was applied to test for a normal distribution of the data. Multiple group comparisons of data, which could thus be assumed to have a normal distribution (data sets of Fn C14 mice, derived from immunohistochemistry and in situ hybridization experiments, except for the data describing immunofluorescence intensity of Fn- and Iba1-staining), were performed using one-way ANOVA followed by Tukey’s Multiple Comparison Test (* P < 0.05; ** P < 0.01; *** P < 0.001). Multiple group comparisons of data that were not compatible with a normal distribution (data sets derived from in vitro assays and real-time qPCR on demethylated tissue, as well as of the data describing immunofluorescence intensity of Fn and Iba1 stainings) were performed using the Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test (*P < 0.05; ** P < 0.01; *** P < 0.001). Nonparametric ranking data, derived from blindly ranking alkaline toluidine blue stained resin sections for estimated degrees of remyelination, were statistically analyzed using the Mann-Whitney test (Ibanez et al., 2004). For the in vivo mice data from immunohistochemistry, in situ hybridization and real time qPCR studies, a representative graph of 2–3 independent experiments is shown, displaying absolute means of 3–4 mice per group and 3 lesions levels per animal, each ~120 μm from each other, with the exception of immunohistochemistry for Iba1, data of which are shown as a relative to the mean immunofluorescence levels of littermate WT controls, set at 100% for each independent experiment. Quantification methods are described under “immunochemistry.” For in vitro proliferation, migration, and adhesion assays, graphs display mean values relative to a control condition (aFn or pFn) from 3 to 5 independent experiments. All error bars represent standard deviations.

**Results**

**Fibronectin in Demyelinated Lesions is Predominantly Produced by Astrocytes**
Transient Fn expression during demyelination is hypothesized to benefit remyelination (Hibbits et al., 2012; Stoffels et al., 2013a; Zhao et al., 2009). The aim of the present study was therefore to better define the potential involvement and underlying mechanism(s) of the different Fn sources in remyelination. We used a well-established rodent model of experimental demyelination, in which focal, primary demyelination is created by the injection of lysolecithin into the white matter of the spinal cord ventral funiculus (Blakemore and Franklin, 2008). Spontaneous and complete remyelination of these lesions proceeds over a period of ~21–28 days in young adult rodents, which involves proliferation and migration of local, activated OPCs to the demyelinated lesions (“recruitment”; 1–10 days post lesion (DPL), followed by differentiation of oligodendrocytes and myelin sheath formation (10–21 DPL) (Zhao et al., 2006). To eliminate pFn and cellular Fn from lysolecithin-demyelinated lesions, we used Cre/lox technology, creating conditional knockout adult mice devoid of plasma Fn (pFn<sup>−/−</sup>), astrocyte Fn (aFn<sup>−/−</sup>) or both (a + pFn<sup>−/−</sup>). The pFn null allele was generated by activation of the Mx-Cre promoter with poly I:C as described (Sakai et al., 2001), which removes the start codon, signal sequence and the exon/intron border of exon 1 from the pFn gene. To remove cellular Fn, we targeted astrocytes, because they are considered a major source of Fn in the CNS following injury (Hibbits et al., 2012), and synthesize pathohological Fn aggregates in MS (Stoffels et al., 2013a). We thus used mice expressing Cre recombinase under control of a GFAP promoter, which was rendered active by exposure to tamoxifen via a modified estrogen receptor. The induction efficiency was tested in a reporter line, as described in a previous report (Hirrlinger et al., 2006). In our own experiments, this approach showed that at 5 days after a course of tamoxifen administration in unlesioned adult mice, of astrocytes in spinal cord white matter on average 78.5% ± 2.4% SD (n = 4) expressed the reporter (yellow fluorescent protein), indicating an efficient recombination.

Using this approach, pFn was successfully eliminated from plasma in pFn<sup>−/−</sup> mice, as revealed by Western blot analysis (Fig. 1A). Similar results were obtained on plasma from a + pFn<sup>−/−</sup> mice, whereas pFn remained present in the plasma of aFn<sup>−/−</sup> mice as expected (Fig. 1B). Given the virtual absence of aFn from the healthy CNS and its increased...
Stoffels et al.: Astrocyte-Derived Fibronectin and OPC Proliferation

expression after demyelination (Stoffels et al., 2013a; Zhao et al., 2009), we assessed local Fn expression in aFncKO and a + pFnKO mice after lysolecithin-induced demyelination of the spinal cord ventral funiculus white matter (Fig. 1C). First, we confirmed that astrocytes are a source of cellular Fn in mouse demyelinated lesions, using immunohistochemistry against GFAP and in situ hybridization for Fn mRNA on WT lesions (Fig. 1D). Further, as shown in Fig. 1E,F, Fn expression was increased in demyelinated lesions of littermate WT mice at 5 DPL, as previously reported for rat models (Stoffels et al., 2013a; Zhao et al., 2009). Moreover, this increase was transient, and Fn levels were decreased in mice at 14 DPL (cf Fig. 5, data not shown), similar to the transient expression pattern of Fn observed in rats (Stoffels et al., 2013a; Zhao et al., 2009). In pFnKO mice, Fn immunostaining was unaltered compared with expression in littermate WT mice (Fig. 1E,F), despite the strong reduction in Fn plasma levels (Fig. 1A). These data indicate that either pFn is not a major source of Fn expression within lysolecithin-induced lesions, or that aFn expression may compensate for the loss of pFn. In contrast, Fn expression was markedly reduced in demyelinated lesions of aFncKO and a + pFnKO mice (Fig. 1E,F), corroborating that astrocytes are a major source of cellular Fn after demyelination. Having reduced Fn levels from plasma and astrocytes, we next analyzed how remyelination was affected at both the recruitment and differentiation stages of remyelination.

**FIGURE 1:** Fibronectin expression is decreased in plasma and demyelinated white matter of plasma, astrocyte, and astrocyte + plasma fibronec-
tin conditional knockout mice. A and B: Western blot analysis for fibronectin (Fn) and immunoglobulin M (IgM) on plasma of littermate wild type (WT) mice and after conditional knockout of Fn from plasma (pFnKO), astrocytes (aFnKO) or astrocytes, and plasma (a + pFnKO). Note the virtual absence of Fn from plasma after pFnKO and a + pFnKO. C: Demyelination was induced by injection of lysolecithin into the white matter of the spinal cord ventral funiculus (red area). D: Immunohistochemistry for DAPI (cell nuclei) and GFAP (astrocytes) combined with in situ hybridization for Fn mRNA on lysolecithin-demyelinated lesions of WT mice at 5 DPL, showing that Fn mRNA is present in astrocytes. E: Immunohistochemistry for Fn on lysolecithin-demyelinated lesions at 5 DPL after pFnKO, aFnKO, a + pFnKO, or in WT mice. F: Quantification of immunofluorescent staining intensities in (E) from 3 mice per group, and 3 lesion levels per animal, ~120 μm distant from each other from images that were taken on the same day using the exact same camera settings. Note the reduction in intensity of immunofluorescence relative to WT after aFnKO and a + pFnKO, but not following pFnKO. Bars represent means. Error bars show standard deviations. Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test (* P < 0.05; ** P < 0.01; *** P < 0.001). Demyelinated lesion outlines were measured in Zeiss Axovision 4.8 software based on the increase in DAPI staining inside the lesions, and outlines are represented by dashed white lines. Scale bar is 20 μm (D) and 50 μm (E). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Proliferation of OPCs in Response to Demyelination is Decreased in Astrocyte Fibronectin Conditional Knockout Mice

To determine whether the density of OPCs in the demyelinated area is affected by pFn<sup>cKO</sup> and/or aFn<sup>cKO</sup>, we analyzed OPC numbers after lysolecithin-induced demyelination in the different Fn<sup>cKO</sup> mice. Immunostaining for Olig2 was used as a marker for oligodendrocyte lineage cells (Arnett et al., 2004; Fancy et al., 2009) and Sox2 and Olig2 double immunohistochemistry to identify OPCs (Kondo and Raff, 2004; Shen et al., 2008; Fig. 2A–D). This approach revealed a small, significant reduction in Olig2-positive (Olig2<sup>1</sup>) cells and Sox2<sup>1</sup>+Olig2<sup>1</sup> cells after aFn<sup>cKO</sup>, but not pFn<sup>cKO</sup> at 5 DPL (Fig. 2A–D). A similar reduction in Olig2<sup>1</sup> and Sox2<sup>1</sup>+Olig2<sup>1</sup> cells was detected after a+pFn<sup>cKO</sup> (Fig. 2A–D), indicating that the decrease in OPC density was associated with the decrease in aFn. An additional decrease in pFn levels in a+pFn<sup>cKO</sup> did not further reduce the number of OPCs. In support of these observations, by determining OPC density using the transcription factor Nkx2.2 as a marker (Watanabe et al., 2004), we similarly detected that the Olig2 density was reduced after aFn<sup>cKO</sup> and a+pFn<sup>cKO</sup> (Fig. 2E,F). The lesions were of comparable sizes in the different Fn<sup>cKO</sup> samples relative to WT (data not shown). In tissue culture, pFn promotes OPC migration and proliferation (Baron et al., 2002; Hu et al., 2009; Milner et al., 1996). To examine whether the reduction in OPC numbers in aFn<sup>cKO</sup> mice reflected an impairment in proliferation, we next analyzed the numbers of proliferating OPCs at 5 DPL, determined by co-labeling with Olig2 and the cell proliferation marker Ki67 (Gerdes et al., 1983). This revealed a reduction in Ki67<sup>+</sup>Olig2<sup>+</sup> cells relative to Olig2<sup>+</sup> cells in aFn<sup>cKO</sup> and a+pFn<sup>cKO</sup>, but not pFn<sup>cKO</sup> (Fig. 2G,H), indicating that the decrease in OPC numbers is, at least partly, a result of impaired proliferation. In contrast, we did not observe a substantial change in microglia/macrophage numbers after Fn<sup>cKO</sup>, as assessed by immunohistochemistry for ionized calcium-binding adaptor molecule 1 (Iba1) (Imai et al., 1996; Fig. 3A,B). Similarly, astrocyte numbers were not significantly affected by Fn<sup>cKO</sup>, as reflected by comparable numbers of cells that stained positive for aldehyde dehydrogenase 1, member L1 (Aldh1L1; Cahoy et al., 2008; Lovatt et al., 2007; Fig. 3C,D). Hence, aFn<sup>cKO</sup> resulted in a reduced number of OPCs after demyelination, whereas microglia/macrophage and astrocyte cell numbers were unaffected.

Oligodendrocyte Differentiation and Remyelination are Not Affected by Conditional Knockout of Fibronectin from Astrocytes

We next examined whether the decreased OPC density observed in aFn<sup>cKO</sup> and a+pFn<sup>cKO</sup> during demyelination resulted in altered CNS remyelination following lysolecithin-induced demyelination. Oligodendrocyte lineage cell numbers were analyzed by immunohistochemistry for Olig2 at 14 days post lysolecithin-induced demyelination. As shown in Fig. 4A,B, Olig2<sup>+</sup> cells were still decreased in a+pFn<sup>cKO</sup> and aFn<sup>cKO</sup> as compared with littermate WT mice. In pFn<sup>cKO</sup> mice, Olig2<sup>+</sup> cell numbers did not differ from the WT mice in the lesions. Furthermore, analysis of differentiated oligodendrocytes, determined by immunohistochemical staining for CC1 (Bhat et al., 1996), showed that the density of CC1<sup>+</sup> cells was similar in all groups (Fig. 4C). This was confirmed using an alternative marker of mature oligodendrocytes, in situ hybridization for proteolipid protein (PLP) mRNA, a major myelin protein, which revealed no differences in PLP mRNA+ cells (Fig. 4D,E). Therefore, despite a reduction of OPCs after demyelination in aFn<sup>cKO</sup> and a+pFn<sup>cKO</sup>, it was not sufficient to result in an impairment of oligodendrocyte generation at 14 DPL.

To assess whether myelin sheath formation was affected, we examined toluidine blue stained semithin resin sections of lesions from littermate WT and a+pFn<sup>cKO</sup> mice at 21 DPL. We could not detect any gross morphological differences between remyelinated lesions from littermate WT and a+pFn<sup>cKO</sup> mice (Fig. 4F). Ranking analysis of the degree of remyelination (Ibanez et al., 2004) did not reveal significant differences between WT and a+pFn<sup>cKO</sup> lesions either (Fig. 4G). Therefore, aFn, although involved in OPC recruitment, is not essential for remyelination.

Expression of the Alternatively Spliced Domains EIIIA and EIIIB mRNA of Cellular Fibronectin is Increased Following Demyelination

We next investigated the specific contribution of the alternatively spliced domains EIIIA and EIIIB, exclusively localized within the cellular Fn structure (Paul et al., 1986; Schwarzbauer et al., 1987) in the regulation of OPC proliferation following demyelination. We first determined the expression of both domains following demyelination of the mouse spinal cord ventral funiculus by quantitative, real-time PCR analysis of mRNA expression. Compared with unlesioned tissue, EIIIA, EIIIB, and total Fn mRNA levels were increased in demyelinated tissue at 5 DPL relative to expression of the housekeeping gene GAPDH (Fig. 5A–C; 5 DPL), similar to our previous report for total Fn protein and Fn EIIIA protein (Stoffels et al., 2013a). Furthermore, during remyelination (14 DPL), mRNA levels of EIIIA, EIIIB, and total Fn returned to lower levels (Fig. 5A–C; 14 DPL). Because both EIIIA and EIIIB mRNA levels are increased at 5 DPL, when OPCs are recruited, and since these elements are exclusively present in Fn derived from local cellular sources, such as astrocytes, we next examined the extent to which aFn EIIIA,
FIGURE 2: OPC numbers in lysolecithin-induced demyelinated lesions decrease after conditional knockout of astrocyte fibronectin, but not after plasma fibronectin conditional knockout alone. A–I: After 5-days post lysolecithin-demyelinated lesions (5 DPL) of the mouse spinal cord ventral funiculus, the density of Olig2-positive ("Olig2+"; A,B), Sox2+ Olig2+ (C,D), Nkx2.2+ (E,F), and KI67+Olig2+ (G,H) cells were determined by immunohistochemistry. Note the decrease in Olig2+, Sox2+Olig2+, Nkx2.2+, and KI67+Olig2+ cells number after conditional knockout of fibronectin from astrocytes (aFncKO) or from astrocytes and plasma (a+pFncKO), but not from plasma alone (pFncKO) relative to littermate WT mice. Images in A,C,E and G are representative images of demyelinated areas in the different groups. Insets show higher power magnifications of the double positive cells that were counted, with the blue color representing DAPI staining. The outline of the demyelinated lesions was measured in Zeiss Axovision 4.8 software based on increased DAPI stainings' inside lesions and outlines are represented by dashed white lines. Double (C,G) or single (A,E) positive cell numbers were manually counted 3 times for 4 mice per group, and 3 lesion levels per animal, ~120 μm distant from each other. Representative graphs of 2–3 independent experiments are shown. Bars represent means. Error bars show standard deviations. Statistical analyses were performed using one-way ANOVA, followed by Tukey’s Multiple Comparison Test (* P < 0.05; ** P < 0.01; *** P < 0.001; NS: not significant). Scale bars are 50 μm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
EIIIA, or both are involved in proliferation and/or migration of OPCs in vitro.

The EIIIA Domain of Astrocyte-Derived Fibronectin Mediates Proliferation of OPCs, but not Their Migration and Adhesion

To examine the effect of pFn and aFn on OPC proliferation, we used commercially available pFn from bovine plasma and aFn derived from extracellular deposits of primary astrocytes (Fig. 6A, “Fn”). The aFn preparation contained the alternatively spliced domain EIIIA (Fig. 6A, “EIIIA”) and EIIIB (Fig. 6A, “EIIIB”), as confirmed by immunostaining with domain-specific antibodies. Functional blocking antibodies against EIIIA (“IST9”, Liao et al., 1999) and EIIIB (“C6”, Balza et al., 2009) were used to eliminate signals from these domains. OPCs were allowed to proliferate on the different substrates in the presence of relatively high levels of PDGF-AA and FGF-2 for 24 h, after which percentages of BrdU-incorporating Olig2+ cells were determined by immunocytochemistry as a measure of OPC proliferation. As expected under these conditions (Baron et al., 2002, Colognato et al., 2004), OPCs proliferated equally well on either aFn (16 ± 5% SD) or pFn (15 ± 8% SD; Fig. 6B), and to comparable levels when grown on PLL (data not shown). However, proliferation of OPCs was markedly reduced when the cells were cultured on aFn with the EIIIA domain blocked (Fig. 6B; “aFn + IST9”). In contrast, addition of the EIIIA blocking antibody to pFn did not affect OPC proliferation (Fig. 6B; “pFn + IST9”), indicating that the reduction in OPC proliferation following the blocking of EIIIA with the IST9 antibody was attributable to the specific effect(s) of the antibody. Moreover, blocking EIIIB from aFn (Fig. 6A; “EIIIB”) with the C6 antibody (Fig. 6B; “aFn + C6”) did not affect OPC proliferation.

To determine whether EIIIA and/or EIIIB of aFn are also important for OPC migration, we allowed OPCs to migrate through transwell microchambers, containing membranes coated with pFn or aFn on both sides, using PDGF-AA as an attractant in the bottom well. As shown in Fig. 6C, migration...
FIGURE 4: Oligodendrocyte differentiation and remyelination are not affected by conditional knockout of fibronectin from astrocytes.

A–E: At 14 days post lysolecithin-induced demyelination (14 DPL) of the spinal cord ventral funiculus, immunohistochemistry (A–C) and in situ hybridization (D,E) were applied to determine the numbers of Olig2+ (A,B), CC1+ (C), and PLP mRNA+ (D,E) cells in littermate WT mice or after conditional knockout of fibronectin from plasma (pFn\textsuperscript{K0}), astrocytes (aFn\textsuperscript{K0}), or astrocytes, and plasma (a+pFn\textsuperscript{K0}). Note the significant decrease of Olig2+ oligodendrocyte lineage cells after aFn\textsuperscript{K0} and a+pFn\textsuperscript{K0} (A,B), whereas the numbers of differentiating oligodendrocytes do not differ from littermate WT mice (C–E). Images in A and D are representative images of demyelinated areas in the different groups. Insets show higher power magnifications of the positive cells that were counted, with the blue color representing DAPI staining. Outlines of demyelinated lesions were measured in Zeiss Axovision 4.8 software based on the increase in DAPI staining inside lesions, and outlines are represented by dashed lines. Cell numbers were manually counted 3 times from 4 mice per group, and 3 lesion levels per animal, ~120 μm distant from each other. Representative graphs of 2–3 independent experiments are shown. Bars represent means of each group. Error bars show standard deviations. Statistical analyses were performed using one-way ANOVA, followed by Tukey’s Multiple Comparison Test (** P<0.01; *** P<0.001; NS: not significant). Scale bars are 50 μm. F,G: At 21 DPL, semi-thin sections of resin-embedded WT and a+pFn\textsuperscript{K0} mice were stained with alkaline toluidin blue to analyze the myelin structure (F), and blindly ranked according to estimated percentage of remyelination by two independent researchers, after which statistical differences were analyzed using the Mann Whitney test (G). Scale bar is 100 μm. NS means “not significant.”

[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
of OPCs was similar on aFn and pFn, and was not affected by blocking the EIIIA or EIIIB domains. These experiments demonstrate that EIIIA, but not EIIIB, is primarily required for proliferation of OPCs on aFn, and that neither domain is essential for migration of OPCs on aFn.

Proliferation of OPCs on pFn at low levels of PDGF-AA is largely mediated by the integrin receptors αvβ3 and to a lesser extent by αvβ1 (Baron et al., 2002; Blaschuk et al., 2000; Milner et al., 1996). Although EIIIA does not directly bind to αvβ1 or αvβ3, it has been reported that EIIIA may indirectly promote adhesion of cellular Fn to these integrins, thereby facilitating proliferation (Manabe et al., 1999). To test this possibility, we assessed whether adhesion of OPCs to aFn indirectly involved integrin β3 binding by using blocking antibodies against integrins β1, β3 and β5, and whether such adhesion was facilitated by functional EIIIA and EIIIB domains. Compared with adhesion to pFn (Fig. 6D; “pFn + β3” and “pFn + β5”), adhesion of OPCs to aFn was only modestly reduced when the integrins β3 (Fig. 6E; “aFn + β3”) and β5 (Fig. 6E; “aFn + β5”) were blocked. In contrast, integrin β1 had no effect on adhesion of OPCs to both pFn and aFn (Fig. 6D,E; “pFn + β1” and “aFn + β1”). Furthermore, functional blocking of EIIIA and EIIIB domains did not alter adhesion of OPCs to aFn (Fig. 6F). Thus, whereas the integrin β3 and β5 receptors likely mediate adhesion of OPCs to aFn, adhesion of OPCs does not require functional EIIIA or EIIIB domains of aFn.

Discussion

In this study, we investigated how Fn, derived from plasma (pFn) or cellular Fn derived from astrocytes (aFn), modulates remyelination following CNS demyelination. After conditional knockout of Fn from astrocytes (aFncKO) or both astrocytes and plasma (a1pFncKO), the density of (proliferating) OPCs in demyelinated lesions was reduced. Our in vitro analyses of OPCs, cultured on either pFn or aFn, revealed that the alternatively spliced EIIIA domain, exclusively present in cellular Fn, is instrumental in proliferation. Our data further showed that this control of proliferation by the EIIIA domain was likely not related to an ability of EIIIA to enhance adhesion of OPCs, although integrins β3 and β5 mediate adhesion of OPCs to aFn. Furthermore, we did not observe an effect of aFn on migration of OPCs. Despite a reduction in oligodendrocyte lineage cells on a1pFncKO at later stages of the remyelination process, both pFn and aFn were dispensable for oligodendrocyte differentiation and complete remyelination.

Although both EIIIA and EIIIB are largely absent from healthy tissue after embryonic development, reappearance of cellular Fn with the alternatively spliced EIIIA and EIIIB domains occurs after injury of different tissue types (ffrench-Constat et al., 1989; Jarnagin et al., 1994; Nickelet et al., 1996; Ulrich et al., 1997). Injury-induced expression of cellular Fn containing EIIIA is associated with increased cell proliferation, as demonstrated in a variety of cell types (Manabe et al., 1999; Olsen et al., 2012; Stenzel et al., 2011). In addition, while proliferation of OPCs is known to be independent
of pFn at sufficient levels of mitogenic growth factors (Baron et al., 2002, Colognato et al., 2004), which are likely also sufficient in lysolecithin-induced demyelinated lesions (Hinks and Franklin, 1999), our data indicate that the EIIIA domain is essential for proliferation of OPCs on aFn under these conditions. This suggests that proliferation of OPCs on aFn involves a different mechanism from pFn. The EIIIA could theoretically mediate proliferation of OPCs on aFn via binding to the integrins \( \alpha_9\beta_1 \) (Olsen et al., 2012; Ou et al., 2013; Sun et al., 2014) and \( \alpha_4\beta_1 \) (Liao et al., 2002), or by enhancing the binding affinity of other integrin receptors for Fn, most notably \( \alpha_5\beta_3 \) and \( \alpha_6\beta_3 \) (Manabe et al., 1997, 1999; Xia and Culp, 1995). However, integrins \( \alpha_4\beta_1 \) and \( \alpha_9\beta_1 \) are not expressed by OPCs (Milner and ffrench-Constat, 1994) and the EIIIA domain was not important for adhesion of OPCs to aFn, implying that EIIIA mediates...
proliferation of OPCs through an alternative mechanism. This mechanism may involve other domains of Fn, since alternative splicing of Fn can change the conformation of Fn, affecting the presentation of binding sequences and exposed cryptic binding sites (Pickford and Campbell, 2004; Ventura et al., 2010). In addition to EIIIA, expression of the EIIIB domain was also upregulated after demyelination. Whereas EIIIB appears not to have a role in proliferation and migration of OPCs, its functional involvement in processes other than proliferation and migration cannot be excluded and merits further investigation.

The apparent redundancy of pFn for achieving a normal cell density of OPCs observed in our in vivo studies was unexpected, given that stimulation of cell proliferation and migration by pFn is well documented for several cell types (To and Midwood, 2011; von Au et al., 2013), including OPCs at low growth factor levels (Baron et al., 2002; Colognato et al., 2004; Hu et al., 2009; Milner et al., 1996). Our in vitro proliferation studies suggested that OPCs proliferate equally on pFn and aFn in the presence of PDGF-AA and FGF-2. After pFnKO, a compensatory increase in cellular Fn may have occurred, mediated by astrocytes, microglia/macrophages, and endothelial cells (Stoffels et al., 2013a). From these cell types, astrocytes are thought to represent the major source of Fn after toxin-induced demyelination (Hibbits et al., 2012; Stoffels et al., 2013a), which is further supported in this study, given the pronounced reduction in Fn levels after aFnKO. Therefore, a compensatory increase in aFn could explain the absence of a clear phenotype after pFnKO, in agreement with studies of other tissues (Sakai et al., 2001). However, the observation that a + pFnKO does not substantially amplify the reduction in OPC numbers during demyelination may support an alternative explanation, namely that excessive leakage of Fn to the demyelinated area does not occur on lysolecithin-induced demyelination, despite breakdown of the blood-brain barrier (Fond et al., 1990). Hence, in contrast to previous studies, in which pFn was considered a predominant source of the Fn matrix in tissue (Moretti et al., 2007), our findings indicate that aFn rather than pFn is the major component of the Fn matrix expressed after lysolecithin-induced CNS demyelination. In MS lesions, where immune-mediated blood-brain barrier disruption is more diffuse, pFn may be a more prominent source of Fn. Also, pFn could potentially modulate OPC proliferation when growth factor levels are low (Baron et al., 2002; Colognato et al., 2004).

Although aFn mediates OPC cell numbers in demyelinated lesions, it is dispensable for remyelination. Moreover, at the stage of oligodendrocyte differentiation, the absolute numbers of differentiated oligodendrocytes did not differ between aFnKO or a + pFnKO and WT animals. After lysolecithin-induced demyelination in WT animals, the amount of differentiating oligodendrocytes remains relatively stable from this stage onwards until the completion of remyelination (Fancy et al., 2004; our unpublished observations). This indicates that despite the reduced numbers of OPCs after aFnKO or a + pFnKO, sufficient numbers of differentiated oligodendrocytes are still generated to reach the maximal level of differentiation necessary to remyelinate the lesion. In this way, relative redundancy of aFn, in spite of decreased OPC proliferation after aFnKO, is consistent with the concept that OPCs are normally recruited in excess relative to the numbers required for remyelination following small, focal, toxin-induced lesions (Franklin and ffrench-Constant, 2008; Stidworthy et al., 2004). In addition, functional compensation may result from the increased expression of several other ECM proteins in demyelinated lesions (Zhao et al., 2009). In support of this, osteopontin, another ECM molecule expressed after demyelination, is also redundant for remyelination (Zhao et al., 2008). In contrast to modulation of OPC proliferation by aFn, which likely promotes recovery, persistent expression of Fn variants in pathology mediates failure of tissue regeneration (Stoffels et al., 2013b). In particular, the EIIIA domain is involved in adverse remodeling after tissue injury (Arslan et al., 2011; Hirshoren et al., 2013; Kohan et al., 2010; Muro et al., 2008). In MS lesions, Fn assembles into aggregates, which is likely mediated by inflammatory factors. Astrocytes are an important source of Fn aggregates, and these Fn aggregates contribute to remyelination failure (Stoffels et al., 2013a). Since our findings indicate that aFn is a nonessential element for remyelination, developing therapeutic approaches that remove aggregates of Fn from MS lesions represent a legitimate translational objective.

**Acknowledgment**

Grant sponsor: The Netherlands Organization of Scientific Research.; Grant sponsor: the Dutch MS Research Foundation.; Grant sponsor: UK MS Society.

Dr. R. Fassler (Max Planck Institute for Biochemistry, Martinsried, Germany) is kindly acknowledged for providing the plasma fibronectin conditional knockout mice. Dr. F. Kirchhoff (Max Planck Institute of Experimental Medicine, Goettingen, Germany) is kindly acknowledged for providing the hGFAP-CreERT2 mice. They also wish to thank Dr. Dan Ma and Dr. Glaucia Monteiro de Castro for their help in optimizing the mouse-on-mouse immunohistochemistry protocol and Dr. Arend H. Sikkema and Charlotte de Jong for expert technical assistance.

**References**

Arnett HA, Fancy SP, Albertia JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD. 2004. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111–2115.

Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. 2011. Lack of...
fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 108:582–592.

Balza E, Sassi F, Ventura E, Parodi A, Fossati S, Blaickow W, Carnemolla B, Castellani P, Zardi L, Borsi L. 2009. A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B. Int J Cancer 125:751–758.

Baron W, Shattil SJ, ffrench-Constant C. 2002. The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins. Embryo J 21:1957–1966.

Bhat RV, Axt KJ, Fosnaugh JS, Smith KJ, Johnson KA, Hill DE, Knizler KW, Baraban JM. 1996. Expression of the APC tumor suppressor protein in oligodendroglia. Glia 17:169–174.

Blakemore WF, Franklin RJM. 2008. Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol 318:193–212.

Balschuk KL, Frost EE, ffrench-Constant C. 2000. The regulation of proliferation and differentiation in oligodendrocyte progenitor cells by alphaV integrins. Development 127:1961–1969.

Bsbibi M, Nomden A, van Noort JM, Baron W. 2012. Toll-like receptors 2 and 3 agonists differentially affect oligodendrocyte survival, differentiation, and myelin membrane formation. J Neurosci Res 90:388–398.

Buttery PC, ffrench-Constant C. 1999. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. Mol Cell Neurosci 14:199–212.

Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubscher JL, Krieg PA, Krupenko SA, Thompson WJ, Barnes BA. 2008. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J Neurosci 28:264–278.

Chari DM, Zhao C, Cotter MR, Blakemore WF, Franklin RJM. 2006. Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system. J Neurosci Res 83:594–605.

Colognato H, Baron W, Avellana-Adalid V, Relvas JB, Baron-Van Evercooren A, Georges-Labouesse E, ffrench-Constant C. 2002. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat Cell Biol 11:833–841.

Duncan ID, Brower A, Kondo Y, Curlee JF Jr, Schultz RD. 2009. Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci USA 106:6832–6836.

Fancy SP, Baranini SE, Zhao C, Uk DJ, Irvine KA, Kaing S, Sanai N, Franklin RJM, Rowitch DH. 2009. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23:1571–1585.

Fancy SP, Zhao C, Franklin RJM. 2004. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol Cell Neurosci 27:247–254.

ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. 1989. Appearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 109:903–914.

Ford CC, Ceckler TL, Karp J, Herndon RM. 1990. Magnetic resonance imaging of experimental demyelinating lesions. Magn Reson Med 14:461–481.

Franklin RJM, ffrench-Constant C. 2008. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 9:839–855.

Franklin RJM, ffrench-Constant C, Edgar JM, Smith KJ. 2012. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8:624–634.

George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:1079–1091.

Gerdes J, Schwab U, Lernke H, Stein H. 1983. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20.

Hibbits N, Yoshino J, Le TQ, Armstrong RC. 2012. Astrogliosisis during acute and chronic cuprizone demyelination and implications for remyelination. ASN Neuro 30:393–408.

Stoffels et al.: Astrocyte-Derived Fibronectin and OPC Proliferation

Hinks GL, Franklin RJM. 1999. Distinctive patterns of PDGF-A, FGF-2, IGF-1, and TGF-b1 gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol Cell Neurosci 14:153–168.

Hirrlinger PG, Scheller A, Braun C, Hirrlinger J, Kirchhoff F. 2006. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2. Glia 54:11–20.

Hirshoren N, Kohan M, Assayag M, Neuman T, Vernea F, Muro A, El-Etr M, Berkman N. 2013. Extra domain-A fibronectin is necessary for the development of nasal remodeling of chronic allergen-induced rhinitis. Allergy Asthma Immunol 110:322–327.

Hu J, Deng L, Wang X, Xu XM. 2009. Effects of extracellular matrix molecules on the growth properties of oligodendrocyte progenitor cells in vitro. J Neurosci Res 87:2854–2862.

Ibanez C, Shields SA, El-Etr M, Baulieu EE, Schumacher M, Franklin RJM. 2004. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol Appl Neuropathol 30:80–89.

Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. 1996. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224:855–862.

Jagamir WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. 1994. Expression of variant fibronectins in wound healing. Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127:2037–2048.

Kohan M, Muro AF, White ES, Berkman N. 2010. EDTA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 24:4503–4512.

Kondo T, Raff M. 2004. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neuronal stem cells. Genes Dev 18:2963–2972.

Lau LW, Keough MB, Haylock-Jacobs S, Cua R, Doring A, Sloka S, Stirling DP, Rivest S, Yong WY. 2012. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol 72:419–432.

Leone DP, Genoud S, Atanasoski S, Grausenburger R, Berger P, Metzger D, Macklin WB, Chambon P, Suter U. 2003. Tamoxifen-inducible glia-specific cre mice for somatic mutagenesis in oligodendrocytes and schwann cells. Mol Cell Neurosci 22:430–440.

Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. 2002. The EIIIA segment of fibronectin is a ligand for integrins alpha(v)beta1 and alpha4beta1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 277:14467–14474.

Liao YF, Wieder KG, Classen JM, Van De Water L. 1999. Identification of two amino acids within the EIIIA (ED-A) segment of fibronectin constituting the epitope for two function-blocking monoclonal antibodies. J Biol Chem 274:17876–17884.

Liesi P, Dahl D, Vaheeri A. 1983. Laminin is produced by early rat astrocytes in primary culture. J Cell Biol 96:920–924.

Liesi P, Kaakkola S, Dahl D, Vaheeri A. 1984. Laminin is induced in astrocytes of adult brain by injury. Embo J 3:683–686.

Lovatt D, Sonnewald U, Waagepetersen HS, Schouboe A, He W, Lin JH, Han X, Takano T, Wang S, Sim FJ, Goldman SA, Nedergaard M. 2007. The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J Neurosci 27:12255–12266.

Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.

Maier O, van der Heide T, van Dam AM, Baron W, de Vries H, Hoekstra D. 2005. Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? Mol Cell Neurosci 28:390–401.
Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. 1997. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol 139:295–307.

Manabe R, Ohe N, Sekiguchi K. 1999. Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 274:5919–5924.

McCarthy KD, de Vellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890–902.

Milner R, Edwards G, Streuli C, ffrench-Constant C. 1996. A role in migration for the alpha V beta 1 integrin expressed on oligodendrocyte precursors. J Neurosci 16:7240–7252.

Milner R, ffrench-Constant C. 1994. A developmental analysis of oligodendroglial genes in primary cells: Changes in alpha v-associated beta subunits during differentiation. Development 120:3497–3506.

Moretti FA, Chauhan AK, Iaconcig A, Porro F, Baralle FE, Muro AF. 2007. A major fraction of fibronectin present in the extracellular matrix of tissues is plasmacytoid. J Biol Chem 282:28057–28062.

Muro AF, Moretti FA, Moore BB, Yan M, Atras RG, Wilke CA, Flaherty KR, Martinez FJ, Tsu JL, Sheppard D, Baralle FE, Toews GB, White ES. 2008. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638–645.

Nickellet V, Kaufman AH, Zagachin L, Dutt JE, Foster CS, Colvin RB. 1996. Healing corneas express embryonic fibronectin isoforms in the epithelium, subepithelial stroma, and endothelium. Am J Pathol 149:549–558.

Olsen AL, Sackey BK, Marcinkiewicz C, Boettiger D, Wells RG. 2012. Fibronectin extra type A domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts. Gastroenterology 142:928–937.

Ou J, Deng J, Wei X, Xie G, Zhou R, Yu L, Liang H. 2013. Fibronectin extra domain A (EDA) sustains CD133(+)CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res 11:820–833.

Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Bruck W, Luchinetti C, Lassmann H. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165–3172.

Paul JI, Schwarzbauer JE, Tamkun JW, Hynes RO. 1986. Cell-type-specific fibronectin subunits generated by alternative splicing. J Biol Chem 261:12258–12265.

Pickford AR, Campbell ID. 2004. NMR studies of modular protein structures and their interactions. Chem Rev 104:3557–3566.

Sakai T, Johnson KJ, Murazono M, Sakai K, Magnuson MA, Wiweloh T, Cronberg T, Ishikai A, Erickson HP, Fassler R. 2001. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 7:324–330.

Satoji JI, Tabunoki H, Yamamura T. 2009. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 15:531–541.

Satoh J, Johnson KJ, Kirk J, Kaplan BM, Hynynen K, Hynynen L, Bulte JW, Weissleder R. 1998. Fibronectin enhances uptake and outgrowth in oligodendrocytes by mislocalizing MMP-9 activity. Mol Cell Neurosci 42:234–242.

Sobel RA, Mitchell ME. 1989. Fibronectin in multiple sclerosis lesions. Am J Pathol 135:161–168.

Stenzel D, Lundkvist A, Sauvaget D, Busse M, Graupera M, van der Flier A, Wijelath ES, Murray J, Sobel M, Costell M, Takahashi S, Fassler R, Yamaguchi Y, Gutmann DH, Hynes RO, Gerhardt H. 2011. Integrin-dependent and independent functions of astrocytic fibronectin in retinal angiogenesis. Development 138:4451–4463.

Stidworthy MF, Genoud S, Li WW, Leone DP, Mantel N, Suter U, Franklin RJM. 2004. Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 127:1928–1941.

Stoffels MJM, de Jonge JC, Stancic M, Norden A, van Strien ME, Ma D, Siskova Z, Maier O, ffrench-Constant C, Franklin RJM, Hoekstra D, Zhao C, Baron W. 2013a. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. Brain 136:116–131.

Stoffels MJM, Zhao C. 2013b. Fibronectin in tissue regeneration: Timely disassembly of the scaffold is necessary to complete the build. Cell Mol Life Sci 70:4243–4253.

Sun XJ, Fa PP, Cui ZW, Xie Y, Sun L, Li ZS, Tang AF, Gui YJ, Cai ZM. 2014. The EDA-containing cellular fibronectin induces epithelial mesenchymal transition in lung cancer cells through integrin alphaVbeta1-mediated activation of PI3-K and Akt1, p191. Carcinogenesis 35:184–191.

To WS, Midwood KS. 2011. Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 4:21.

Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F, Smits JP. 1997. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol 29:2533–2543.

van Hasselt J, Bo L, Vas CM, Virtanen I, de Vries HE. 2005. Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: Potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol 64:722–729.

Ventura E, Sassi F, Parodi A, Balza E, Borsl I, Castellani P, Carmelilla B, Zardi L. 2010. Alternative splicing of the angiogenesis associated extra-domain A of fibronectin regulates the accessibility of the B-C loop of the type III repeat B. PLoS One 5:e9145.

von Au A, Vasel M, Kraft S, Sens C, Hackl N, Marx A, Strobel P, Hennenlotter J, Todenhöfer T, Stenzl A, Schott S, Sinn HP, Wetterwald A, Bermejo JL, Cecchini MG, Nakchbandi IA. 2013. Circulating fibronectin controls tumor growth. Neoplasia 15:925–938.

Watanabe M, Hadzic T, Nishiyama A. 2004. Transient upregulation of Nkg2D expression in oligodendrocyte lineage cells during remyelination. Glia 46:311–322.

Xia P, Culp LA. 1995. Adhesion activity in fibronectin’s alternatively spliced domain EIIIA: Complementarity to plasma fibronectin functions. Exp Cell Res 217:517–527.

Zawadzka M, Rivers LE, Fancy SP, Zhao C, Tripathi R, Jemen F, Young K, Gonchararevich A, Pohl H, Rizzi M, Rowitch DH, Kessaris N, Suter U, Richardson WD, Franklin RJM. 2010. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 6:578–590.

Zhao C, Fancy SP, ffrench-Constant C, Franklin RJM. 2008. Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination. Neurobiol Dis 31:209–217.

Zhao C, Fancy SP, Franklin RJM, ffrench-Constant C. 2009. Up-regulation of oligodendrocyte precursor cell alphaV integrin and its extracellular ligands during central nervous system remyelination. J Neurosci Res 87:3447–3455.

Zhao C, Li WW, Franklin RJM. 2006. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 27:1296–1307.